Skip to main content

Table 2 Adjusted mean change* from baseline to last value on treatment in total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides

From: Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials

   Linagliptin 5 mg (n = 366) Placebo (n = 146)
   Mean (SE) Mean (SE)
Total cholesterol, mg/dl Baseline 180.4 (1.1) 177.2 (1.6)
  Change from baseline -0.4 (1.0) 2.1 (1.3)
  Placebo-corrected difference -1.8 (1.4)
    95% CI -4.4, 0.9
    P value 0.195
LDL, mg/dl Baseline 144.5 (1.9) 142.3 (2.9)
  Change from baseline 2.2 (1.8) 4.1 (2.3)
  Placebo-corrected difference -1.8 (2.4)
    95% CI -6.6, 3.0
    P value 0.452
HDL, mg/dl Baseline 40.2 (1.1) 40.0 (1.9)
  Change from baseline 1.5 (0.6) 2.6 (0.8)
  Placebo-corrected difference -1.2 (0.8)
    95% CI -2.8, 0.5
    P value 0.172
Triglycerides, mg/dl Baseline 272.6 (12.5) 241.0 (10.1)
  Change from baseline -18.5 (7.7) -13.5 (9.9)
  Placebo-corrected difference -5.0 (10.6)
    95% CI -25.9, 15.9
    P value 0.6360
SBP, mm Hg Baseline 137.8 (0.8) 134.8 (1.3)
  Change from baseline -2.9 (0.9) -2.4 (1.2)
  Placebo-corrected difference -0.6 (1.3)
    95% CI -3.1, 2.0
    P value 0.664
DBP, mm Hg Baseline 80.5 (0.5) 81.4 (0.8)
  Change from baseline -1.2 (0.6) -1.0 (0.8)
  Placebo-corrected difference -0.2 (0.8)
    95% CI -1.9, 1.4
    P value 0.773
  1. *Adjusted for baseline HbA1c, parameter measured, prior OADs, study and treatment.
  2. Patient numbers varied for each parameter. For linagliptin, total cholesterol n = 351, LDL n = 349, HDL n = 348, triglycerides n = 349, SBP n = 359, DBP n = 359. For placebo, total cholesterol n = 140, LDL n = 139, HDL n = 140, triglycerides n = 139, SBP n = 144, DBP n = 144.
  3. DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LVOT, last value on treatment; SBP, systolic blood pressure.